Human epidermal growth factor receptor 2 (HER2) is amplified and/or overexpressed in 15–20 % of breast cancers [1] and in 10–24 % of gastric/gastroesophageal junction cancers [2, 3]. The gene discussed is ERBB2; the disease is breast carcinoma.